SAN DIEGO, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) ( www.apricusbio.com) announced today that Steve Martin, Interim Chief Executive Officer and Chief Financial Officer, will present at the 15 th Annual BIO CEO & Investor Conference, being held at The Waldorf Astoria in New York City. Mr. Martin's presentation will take place on Tuesday, February 12, 2013 at 10:00 a.m. Eastern Time. The presentation will be webcast and accessible to the public online at http://www.veracast.com/webcasts/bio/ceoinvestor2013/05208163.cfm or via the Company's website at http://www.apricusbio.com. A replay will be available for 90 days after the presentation. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China. For further information on Apricus Bio, visit http://www.apricusbio.com. You can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations: David Pitts Argot Partners 212-600-1902 firstname.lastname@example.org